Oramed Pharmaceuticals Logo
US68403P2039
A1CTNU
ORMP.TA

Oramed Pharmaceuticals

Prévisions

Acheter
  6
Conserver
  2
Vendre
  0

Discussions dans la communauté

Il n'y a pas encore de discussion sur cet actif.

Lancer une discussion

  • Lifeward shareholders approve partnership with Oramed and potential capital injection

    Lifeward has approved the issuance of common shares as part of a strategic partnership with Oramed, potentially giving the company access to up to about $47 million from Oramed and an additional investor. The financing includes equity, convertible bonds, milestone payments and warrants. Oramed will manage and fund the clinical development program for the POD technology, which aims to enable oral delivery of biopharmaceuticals, while Lifeward will focus on its medical technology business. Lifeward shares jumped more than 10% after the announcement but remain down around 65% year-to-date; completion of the transaction is still subject to customary conditions. » Plus sur de.investing.com


  • Oramed receives $18 million from Scilex and announces cash dividend

    Oramed has received a payment of $18 million from Scilex, fulfilling all obligations under an option agreement and raising the total return on the original $99.5 million investment to $118 million. Oramed also retains a $27 million promissory note, a $12 million convertible note (conversion price $36 per share), warrants and a nine‑year royalty/license interest in Scilex products. The board approved a cash dividend of $0.25 per share (ex‑date January 16, 2026; payment January 26, 2026), to be financed from surplus funds; the share price then rose by about 6.2%. » Plus sur de.investing.com


  • Oramed Pharmaceuticals: Leonard Sank steps down from director post after 18 years

    Leonard Sank has announced he will resign his mandate on the supervisory board of Oramed Pharmaceuticals effective January 1, 2026. The company emphasizes that his resignation is not due to disagreements over management, policies, or practices. Sank served 18 years as a director. » Plus sur de.investing.com


  • Oramed completes repurchase of Scilex warrants for $28.5m

    Oramed received a total of $28.5 million from Scilex for the repurchase of warrants to acquire 6,500,000 Scilex common shares (two tranches: 3,370,000 shares for $14 million and 3,130,000 shares for $13 million, plus $1.5 million in option fees). The warrants had an exercise price of $0.01 and were repurchased under an agreement disclosed in July. In addition, Oramed repurchased 1,155,367 of its own common shares for about $2.58 million and ended a joint venture with HTIT/Technowl; the company now plans to continue its oral insulin program independently and to initiate a new U.S. study. » Plus sur de.investing.com


  • Oramed buys back HTIT shares and ends joint venture

    Oramed repurchased 1,155,367 common shares of Hefei Tianhui Biotech (HTIT) at $2.23 each (about $2.58 million) and had the shares cancelled. The company terminated the joint-venture agreement with HTIT and Technowl after HTIT failed to meet closing conditions. Oramed released preliminary, unaudited financials as of September 30, 2025, and launched a new U.S. study for its oral insulin program with 60 identified high responders. It also completed the first tranche of an option repurchase agreement with Scilex (3,130,000 shares for $13 million) and increased the number of authorized shares under its stock option plan by 2,000,000 to 9,500,000. » Plus sur de.investing.com

En 2026, Oramed Pharmaceuticals a déjà versé 0,21 € de dividendes. Le dernier versement a eu lieu en janvier.

Données financières

Au dernier trimestre, Oramed Pharmaceuticals a réalisé un chiffre d'affaires de 0 € et un bénéfice net de 16,25 M €

(EUR) septembre 2026
YoY
Chiffre d'affaires 0 -
Bénéfice brut 0 100,00 %
Bénéfice net 16,25 M 60,59 %
EBITDA 24,99 M 50,69 %

Données fondamentales

Indicateur Valeur
Capitalisation boursière
141,48 M €
Nombre d'actions
43,49 M
Plus haut/bas sur 52 semaines
4,99 € - 2,30 €
Rendement du dividende
6,00 %
Dividendes TTM
0,21 €
Bêta
1,28
Ratio P/E
1,02
Ratio PEG
0,00
Ratio P/B
0,44
Ratio P/S
0,00

Profil de l'entreprise

Oramed Pharmaceuticals Inc. se consacre à la recherche et au développement de solutions pharmaceutiques destinées au traitement du diabète et à l'utilisation de capsules ou de pilules ingérables par voie orale pour l'administration de polypeptides. Son produit phare propriétaire est l'ORMD-0801, une capsule d'insuline ingérable par voie orale, qui a achevé les essais cliniques de phase II pour le traitement des personnes atteintes de diabète. La société développe également l'ORMD-0901, une capsule orale de peptide-1 analogue au glucagon, qui a achevé les essais cliniques de phase I pour le traitement du diabète de type 2 ; ainsi qu'un traitement de perte de poids sous forme de capsule orale de leptine. La société était auparavant connue sous le nom d'Integrated Security Technologies, Inc. et a changé sa dénomination en Oramed Pharmaceuticals Inc. en avril 2006. Oramed Pharmaceuticals Inc. a été fondée en 2002 et son siège se trouve à New York, New York.

Nom
Oramed Pharmaceuticals
PDG
Nadav Kidron
Siège social New York City, ny
États-Unis
Site web
Secteur
Matériaux
Industrie
Produits chimiques
Introduction en bourse
01/05/2007
Employés 13

Symboles boursiers

Bourse Symbole
Tlv
ORMP.TA
NASDAQ
ORMP
Frankfurt
OJU1.F
Düsseldorf
OJU1.DU
München
OJU1.MU
🍪

Parqet  utilise des cookies. En savoir plus